TSX:IGX 0.67 +0.00 +0% Volume: 32,000 November 24, 2015
OTCQX: IGXT 0.51 +0.02 +3.06% Volume: 131,625 November 25, 2015

Horst Zerbe, CEO, Founder, IntelGenx Technologies Corp (IGXT)

IntelGenx, through its cutting edge formulation platforms, has developed a broad and diverse product portfolio, including products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products.


IntelGenx has three proprietary delivery platforms, including an immediate release oral film, VersaFilm™, a mucoadhesive tablet, AdVersa™ and multilayer controlled release tablet, VersaTab™. IntelGenx has an aggressive product development initiative that primarily focuses on addressing unmet market needs. Our rapidly growing product pipeline consists of products at various stages of development from inception to commercialization.


We are proud of our ability to provide and develop a wide and highly diverse range of products catering for present and future commercial needs. Our highly qualified and diversified team provides expertise and services in the following area: formulation development, analytical testing and method development, scale up and technology transfer, manufacturing support, regulatory, clinical research and intellectual properties.

General Information

IntelGenx Corp.
6425 Abrams
Ville St-Laurent (Quebec)
H4S 1X9
Tel: 514-331-7440
Fax: 514-331-0436

Investor Relations - USA

Edward Miller
Director, Investor Relations
6420 Abrams
Saint-Laurent, Quebec H4S 1Y2
T: 514-331-7440 x217